Next generation antibiotics inspired by nature

Obulytix revolutionizes the fight against antimicrobial resistance

with its proprietary platform for phage lysin-based antibiotics

About

The world is facing an unprecedented antimicrobial resistance crisis with regular antibiotics losing their efficacy against antibiotic-resistant bacteria. Obulytix is a biotechnology company focused on the discovery and development of a groundbreaking class of enzyme-based antibiotics to combat the most severe antibiotic-resistant bacteria.

Armed with our expertise and great commitment, we're here to make a real difference. Our mission is to provide concrete solutions to this pressing global challenge and to save the lives of countless patients battling life-threatening conditions.

Our Solution

Phage lysins are powerful enzymes derived from bacterial viruses known as bacteriophages, and are the cornerstones of our groundbreaking approach. These miniscule scissors are great in degrading bacterial cell walls, killing bacteria on a second scale. Their innovative mode of action sets them apart as a revolutionary class of antibiotics, offering unique advantages such as specificity, absence of resistance development, and the capability to combat chronic infections, marking a profound shift in antibiotic innovation.

Each successful phage lysin is a unique combination of nature's building blocks. These building blocks are found in nature in a practically unlimited number and diversity. At Obulytix, we master the art of tailoring phage lysins into powerful antimicrobials that can eradicate harmful bacteria.

Our Technology

Obulytix presents a technology platform that truly sets us apart. We've adapted the highly successful hit-to-lead process from drug discovery to the domain of phage lysin-based antibiotics. Based on our proprietary VersaTile method and backed by years of expertise, our platform excels in both efficiency and throughput, leveraging the power of artificial intelligence. Our approach catapults phage lysin development into the era of digital biology.

Our cutting-edge platform is dedicated to the development of phage lysins targeting extensively drug-resistant Gram-negative bacteria. These superbugs pose a significant threat, particularly to patients in intensive care units who are facing critical medical conditions. Obulytix is at the forefront, using our platform to deliver effective solutions for these critical situations, saving lives, and pioneering a new era in antibiotic research.